PPARγ/PGC-1α pathway in E-cadherin expression and motility of HepG2 cells

Anticancer Research

Volumn 29, Issue 12, 2009, Pages 5057-5063

  Lee, Hui Ju ^a   Su, Yeu ^a   Yin, Pen Hui ^b   Lee, Hsin Chen ^a   Chi, Chin Wen ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Hepatocellular carcinoma; Metastasis; Migration; Peroxisome proliferator activated receptor gamma; siRNA

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; ROSIGLITAZONE; SMALL INTERFERING RNA; TROGLITAZONE; UVOMORULIN;

ARTICLE; CELL MIGRATION; CELL MOTILITY; CELL STRAIN HEPG2; ENZYME ACTIVATION; GENE OVEREXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CADHERINS; CELL MOVEMENT; HEAT-SHOCK PROTEINS; HEP G2 CELLS; HUMANS; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 75149166058     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Department of Health, Executive Yuan, Health Statistics of the Republic of China, Taipei, Taiwan, ROC: Vital-Statistic, 2007.
2. Bruix J, Boix L, Sala M and Llovet JM: Focus on hepatocellular carcinoma. Cancer Cell 5: 215-219, 2004.
3. Llovet JM and Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48: 1312-1327, 2008.
4. Desvergne B and Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20: 649-688, 1999.
5. Lehrke M and Lazar MA: The many faces of PPARgamma. Cell 123: 993-999, 2005.
6. Grommes C, Landreth GE and Heneka MT: Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 5: 419-429, 2004.
7. Annicotte JS, Iankova I, Miard S, Fritz V, Sarruf D, Abella A, Berthe ML, Noel D, Pillon A, Iborra F, Dubus P, Maudelonde T, Culine S and Fajas L: Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol 26: 7561-7574, 2006.
8. Nemenoff RA: Peroxisome proliferator-activated receptor-gamma in lung cancer: defining specific versus 'off-target' effectors. J Thorac Oncol 2: 989-992, 2007.
9. Jeanes A, Gottardi CJ and Yap AS: Cadherins and cancer: how does Cadherin dysfunction promote tumor progression? Oncogene 27: 6920-6929, 2008.
10. Ondrey F: Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin Cancer Res 15: 2-8, 2009.
11. Spiegelman BM and Heinrich R: Biological control through regulated transcriptional coactivators. Cell 119: 157-167, 2004.
12. Puigserver P, Adelmant G, Wu Z, Fan M, Xu J, O'Malley B and Spiegelman BM: Activation of PPARgamma coactivator-1 through transcription factor docking. Science 286: 1368-1371, 1999.
13. Puigserver P, Wu Z, Park CW, Graves R, Wright M and Spiegelman BM: A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92: 829-839, 1998.
14. Finck BN and Kelly DP: PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 116: 615-622, 2006.
15. Jiang WG, Douglas-Jones A and Mansel RE: Expression of peroxisome-proliferator activated receptor-gamma (PPARγ) and the PPARgamma co-activator, PGC-1, in human breast cancer correlates with clinical outcomes. Int J Cancer 106: 752-757, 2003.
16. Feilchenfeldt J, Brundler MA, Soravia C, Totsch M and Meier CA: Peroxisome proliferator-activated receptors (PPARs) and associated transcription factors in colon cancer: reduced expression of PPARgamma-coactivator 1 (PGC-1). Cancer Lett 203: 25-33, 2004.
17. Schaefer KL, Wada K, Takahashi H, Matsuhashi N, Ohnishi S, Wolfe MM, Turner JR, Nakajima A, Borkan SC and Saubermann LJ: Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res 65: 2251-2259, 2005.
18. Kristiansen G, Jacob J, Buckendahl AC, Grutzmann R, Alldinger I, Sipos B, Kloppel G, Bahra M, Langrehr JM, Neuhaus P, Dietel M and Pilarsky C: Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times. Clin Cancer Res 12: 6444-6451, 2006.
19. Lee HJ, Su Y, Lui WY, Chau GY, Yin PH, Lee HC and Chi CW: Peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) up-regulated E-cadherin expression in HepG2 cells. FEBS Lett 582: 627-634, 2008.
20. Vichai V and Kirtikara K: Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1: 1112-1116, 2006.
21. Yu J, Qiao L, Zimmermann L, Ebert MP, Zhang H, Lin W, Rocken C, Malfertheiner P and Farrell GC: Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 43: 134-143, 2006.
22. Potter E, Bergwitz C and Brabant G: The cadherin-catenin system: implications for growth and differentiation of endocrine tissues. Endocr Rev 20: 207-239, 1999.
23. Howard EW, Camm KD, Wong YC and Wang XH: E-Cadherin up-regulation as a therapeutic goal in cancer treatment. Mini Rev Med Chem 8: 496-518, 2008.
24. Zhang W, Wu N, Li Z, Wang L, Jin J and Zha XL: PPARgamma activator rosiglitazone inhibits cell migration via up-regulation of PTEN in human hepatocarcinoma cell line BEL-7404. Cancer Biol Ther 5: 1008-1014, 2006.
25. Wang PS, Chou FS, Porchia L, Saji M and Pinzone JJ: Troglitazone inhibits cell migration, adhesion, and spreading by modulating cytoskeletal rearrangement in human breast cancer cells. Mol Carcinog 47: 905-915, 2008.
26. Wu Y, Chin WW, Wang Y and Burris TP: Ligand and coactivator identity determines the requirement of the charge clamp for coactivation of the peroxisome proliferator-activated receptor gamma. J Biol Chem 278: 8637-8644, 2003.
27. Li Y, Kovach A, Suino-Powell K, Martynowski D and Xu HE: Structural and biochemical basis for the binding selectivity of peroxisome proliferator- activated receptor gamma to PGC-1alpha. J Biol Chem 283: 19132-19139, 2008.
28. Bren-Mattison Y, Van Putten V, Chan D, Winn R, Geraci MW and Nemenoff RA: Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small cell lung cancer cells (NSCLC). Oncogene 24: 1412-1422, 2005.
29. Weng JR, Chen CY, Pinzone JJ, Ringel MD and Chen CS: Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocr Relat Cancer 13: 401-413, 2006.